52
Participants
Start Date
October 14, 2019
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
UCART22
Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
CLLS52
A monoclonal antibody that recognizes a CD52 antigen
RECRUITING
Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
WITHDRAWN
Weill Medical College of Cornell University, New York
RECRUITING
Roswell Park Comprehensive Cancer Center, Buffalo
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
RECRUITING
CHU Rennes - Hopital Pontchaillou, Rennes
RECRUITING
Sarah Cannon - HCA Research Institute, Nashville
RECRUITING
CHU de Nantes - Hôtel-Dieu, Nantes
RECRUITING
University of Wisconsin Carbone Cancer Center, Madison
RECRUITING
University of Chicago, Chicago
RECRUITING
Hôpital Lyon Sud, Pierre-Bénite
RECRUITING
Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'Hématologie, Paris
RECRUITING
Hôpital Robert Debré - Service d'hémato-immunologie, Paris
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio
RECRUITING
Sarah Cannon - St. David's South Austin Medical Center, Austin
RECRUITING
University of Colorado - Aurora Cancer Center, Aurora
RECRUITING
Sarah Cannon - Colorado Blood Cancer Institute, Denver
RECRUITING
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
RECRUITING
Dana Farber Cancer Institute, Boston
Lead Sponsor
Cellectis S.A.
INDUSTRY